Pages that link to "Q92398872"
Jump to navigation
Jump to search
The following pages link to Joseph Mikhael (Q92398872):
Displaying 30 items.
- Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma (short title) (Q26782868) (← links)
- Smoldering multiple myeloma requiring treatment: time for a new definition? (Q26996579) (← links)
- Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines (Q28290236) (← links)
- Salvage second hematopoietic cell transplantation in myeloma (Q30416452) (← links)
- Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma (Q33386052) (← links)
- Pomalidomide, Bortezomib and Dexamethasone (PVD) for Patients with Relapsed, Lenalidomide Refractory Multiple Myeloma (Q33443411) (← links)
- Conflicts of interest, authorship, and disclosures in industry-related scientific publications (Q33620440) (← links)
- Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients (Q33680252) (← links)
- Trends and outcomes of modern staging of solitary plasmacytoma of bone (Q35632671) (← links)
- Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease (Q35794132) (← links)
- Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis (Q36015183) (← links)
- Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial (Q36163205) (← links)
- Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone (Q37268930) (← links)
- Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines (Q37454445) (← links)
- Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial (Q37515416) (← links)
- Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study (Q37655019) (← links)
- Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. (Q38094334) (← links)
- Treatment of Immunoglobulin Light Chain Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement (Q38562143) (← links)
- Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016. (Q38774535) (← links)
- Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy (Q39177792) (← links)
- Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group (Q39214847) (← links)
- Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR Analysis (Q39518931) (← links)
- Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib (Q40532419) (← links)
- A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma (Q44273992) (← links)
- Pomalidomide – An Appraisal of Its Clinical Development and Role in the Treatment of Relapsed/Refractory Multiple Myeloma (Q57904293) (← links)
- Immunoglobulin D amyloidosis: a distinct entity (Q60976548) (← links)
- The definition of IgM multiple myeloma (Q60976598) (← links)
- Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma (Q90648466) (← links)
- A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma (Q92309462) (← links)
- Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score (Q92398877) (← links)